Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
Kim, Vickie (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S214010, C514S215000, C514S290000, C514S357000, C514S339000
Reexamination Certificate
active
06852741
ABSTRACT:
The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by co-administration of metanicotine and at least one compound which exhibits antagonist activity, or both agonistic and antagonists activity, toward one or more nicotinic acetylcholine receptor subtypes. The subject invention, in another aspect, pertains to pharmaceutical compositions containing metanicotine and at least one compound which inhibits antagonistic activity, or both agonistic and antagonistic activity, toward one or more nicotinic acetylcholine receptor subtypes.
REFERENCES:
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5726316 (1998-03-01), Crooks et al.
patent: 5885998 (1999-03-01), Bencherif et al.
patent: 5977144 (1999-11-01), Meyer et al.
patent: 6218383 (2001-04-01), Bencherif
patent: 6224897 (2001-05-01), Reitberg
patent: 6277855 (2001-08-01), Yerxa
patent: WO 200182978 (2001-11-01), None
“Radiosynthesis and PET studies of [11C]RJR-2403, a nicotinic agonist”, Studenov et al., abstract, Journal of Labelled Compounds & Radiopharmaceuticals, 2001, 44(6), 425-436.*
“Nicotinic treatment of Alzheimer's disease”, Newhouse et al., Society of Biological Psychiatry, 2001, 49:268-278.*
Adler, L.E. et al. “Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relatives of Schizophrenics”Biol. Psychiatry,1992, 32:607-616.
Adler, L.E. et al. “Normalization of Auditory Physiology by Cigarette Smoking in Schizophrenic Patients”Am. J. Psychiatry,1993, 150:1856-1861.
Adler, L.E. et al. “Schizophrenia, Sensory Gating, and Nicotinic Receptors”Schizophr. Bull.,1998, 24(2):189-202.
Arneric, S.P. et al. “Neuronal Nicotinic Acetylcholine Receptors”Psychopharmacology: The Fourth Generation of Progress,1995, pp. 95-110.
Bencherif, F. et al. “RJR-2403: A Nicotinic Agonist with CNS Selectivity I. In Vitro Characterization”J. Pharmacol. Exp. Ther.,1996, 279:1413-1421.
Benowitz, N.L. “Pharmacology of Nicotine: Addiction and Therapeutics”Annu. Rev. Pharmacol. Toxicol.,1996, 36:597-613.
Cosford, N.D.P. et al. “(S)-(−)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine Maleate (SIB-1508Y): A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors”J. Med. Chem.,1996, 39:3235-3237.
Cosford, N.D.P. et al. “Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist”Pharm. Acta. Helv.,2000, 74:125-130.
Damaj, M.I. et al. “Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist”J. Pharmacol. Exp. Ther.,1999, 291(1):390-398.
De Fiebre, C.M. et al., “Characterization of a Series of Anabaseine-Derived Compounds Reveals that the 3-(4)-Dimethylaminocinnamylidine Derivative is a Selective Agonist at Neuronal Nicotinic α7/125I-α-Bungarotoxin Receptor Subtypes”Mol. Pharmacol.,1995, 47:164-171.
Donnelly-Roberts, D.L. et al. “ABT-594 [(R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine]: A Novel, Orally Effective Analgesic Acting via Neuronal Nicotine Acetylcholine Receptors: I. In Vitro Characterization”J. Pharmacol. Exp. Ther.,1998, 285:777-786.
Flores, C.M. et al. “A Subtype of Nicotinic Cholinergic Receptor in Rat Brain is Composed of α4 and β2 Subunits and is Up-regulated by Chronic Nicotine Treatment”Mol. Pharmacol.,1992, 41:31-37.
Freedman, R. et al. “Schizophrenia and Nicotinic Receptors”Harvard Rev. Psychiatry,1994, 2(4):179-192.
Freedman, R. et al. “The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia”J. of Chemical Neuroanatomy,2000, 20:299-306.
Gerzanich, V. et al. “α5 Subunit Alters Desensitization, Pharmacology, Ca++Permeability and Ca++Modulation of Human Neuronal α3 Nicotinic Receptors”J. Pharmacol. Exp. Ther.,1998, 286(1):311-320.
Halvorsen, S.W. and D.K. Berg “Subunit Composition of Nicotinic Acetylcholine Receptors from Chick Ciliary Ganglia”J. Neurosci.,Jun. 1990, 10(6):1711-1718.
Holladay, M.W. et al. “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery”J. Med. Chem.,Dec. 19, 1997, 40(26):4169-4194.
Lippiello, P.M. et al. “RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization”J. Pharmacol. Exp. Ther.,1996, 279:1422-1429.
Lloyd, G.K. et al. “The Potential of Subtype-Selective Neuronal Nicotinic Acetylcholine Receptor Agonists as Therapeutic Agents”Life Sciences,1998, 62(17/18):1601-1606.
Lloyd, G.K. and M. Williams “Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets”J. Pharmacol.,2000, 292(2):461-467.
Meyer, E.M. et al. “3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner”Brain Res.,1997, 768:49-56.
Mihailescu, S. and R. Drucker-Colin “Nicotine, Brain Nicotinic Receptors, and Neuropsychiatric Disorders”Arch. Med. Res.,2000, 31:131-144.
Miller, C. “Genetic Manipulation of Ion Channels: A New Approach to Structure and Mechanism”Neuron,1988, 2:1195-1205.
Mulle, C. et al. “Existence of Different Subtypes of Nicotinic Acetylcholine Receptors in the Rat Habenulo-interpeduncular System”J. Neurosci.,Aug. 1991, 11(8):2588-2597.
Newhouse, P.A. et al. “Nicotinic System Involvement in Alzheimer's and Parkinson's Diseases”Drugs Aging,Sep. 1997, 11(3):206-228.
Newhouse, P.A. and M. Kelton “Nicotinic systems in central nervous systems disease: degenerative disorders and beyond”Pharm. Acta. Helv.,2000, 74:91-101.
Papke, R.L. “The Kinetic Properties of Neuronal Nicotinic Receptors: Genetic Basis of Functional Diversity”Prog. Neurobiol.,1993, 41:509-531.
Papke, R.L. “Activation and inhibition of rat neuronal nicotinic receptors by ABT-418”Br. J. Pharmacol.,1997, 120:429-438.
Papke, R.L. et al. “The Activation and Inhibition of Human Nicotinic Acetylcholine Receptor by RJR-2403 Indicate a Selectivity for the α4β2 Receptor Subtype”J. Neurochem.,2000, 75:204-216.
Papke, R.L. et al. “α7 Receptor-selective agonists and modes of α7 receptor activation”Eur. J. Pharmacol.,2000, 393:170-195.
Papke, R.L. et al. “Inhibition of Wild-Type and Mutant Neuonal Nicotinic Acetylcholine Receptors by Local Anesthetics”Mol. Pharm.,2001, 60:1365-1374.
Rusted, J.M. and P.A. Newhouse “Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease”Behav. Brain. Res.,2000 113:121-129.
Sanberg, P.R. et al. “Treatment of Tourette's syndrome with mecamylamine”Lancet,Aug. 29, 1998, 352:705-706.
Silver, A.A. et al. “Case Study: Long-Term Potentiation of Neuroleptics with Transdermal Nicotine in Tourette's Syndrome”J. Am. Acad. Child Adolesc. Psychiatry,Dec. 1996, 35:1631-1636.
Sullivan, J.P. et al. “ABT-089 [2-Methyl-3(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties”J. Pharmacol. Exp. Ther.,1997, 283(1):235-246.
Vernier, J. et al. “4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]-phenol Hydrochloride (SIB-1553A): A Novel Cognitive Enhancer with Selectivity for Neuronal Nicotinic Acetylcholine Receptors”J. Med. Chem.,1999, 42:1684-1686.
Vidal, C. “Nicotinic Receptors in the Brain”Mol. Chem. Neuropathol.,1996, 28:3-11.
Wang, F. et al. “Assembly of Human Neuronal Nicotinic Receptor α5 Subunits with α3, β2, and β4 Subunits”J. Biol. Chem.,Jul. 1996, 271(30):17656-17665.
Webster,
Kim Vickie
Kwon Brian-Yong S.
Saliwanchik Lloyd & Saliwanchik
University of Florida
LandOfFree
Compositions and methods for treatment of neurological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of neurological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of neurological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470643